Fineline Cube

Follow:
14486 Articles
GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines
Company

GSK Reports 6% Sales Growth in Q2 2025, Driven by Specialty Medicine and Vaccines

CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086
CompanyDeals

CSPC Signs Exclusive Licensing Deal with Madrigal for GLP-1 Agonist SYH2086

HRAIN Biotech's HICARA Approved by NMPA for Relapsed/Refractory LBCL
CompanyDrug

HRAIN Biotech’s HICARA Approved by NMPA for Relapsed/Refractory LBCL

Eli Lilly's Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial
CompanyDrug

Eli Lilly’s Jaypirca Achieves Primary Endpoint in Phase III BRUIN CLL-314 Trial

Shanghai Pharmaceuticals' B019 Injection Approved for SLE Clinical Trials
CompanyDrug

Shanghai Pharmaceuticals’ B019 Injection Approved for SLE Clinical Trials

Bayer's Sevabertinib Granted Priority Review by China's NMPA for NSCLC Treatment
CompanyDrug

Bayer’s Sevabertinib Granted Priority Review by China’s NMPA for NSCLC Treatment

LTZ Therapeutics and Eli Lilly Partner to Develop Myeloid Engager Therapeutics
CompanyDeals

LTZ Therapeutics and Eli Lilly Partner to Develop Myeloid Engager Therapeutics

Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01
CompanyDrug

Huadong Medicine Receives NMPA Approval for Phase III Trial of Psoriasis Cream MC2-01

China Medical System's ZUNVEYL NDA Accepted by China's NMPA for Alzheimer's Treatment
Others

China Medical System’s ZUNVEYL NDA Accepted by China’s NMPA for Alzheimer’s Treatment

MSD’s Q2 Earnings Hit by Gardasil Sales Decline, Keytruda Growth Slows
Company

MSD’s Q2 Earnings Hit by Gardasil Sales Decline, Keytruda Growth Slows

Novo Nordisk Shares Plummet 20% as Obesity Drug Competition Intensifies and Full-Year Guidance Lowered
Company

Novo Nordisk Shares Plummet 20% as Obesity Drug Competition Intensifies and Full-Year Guidance Lowered

YolTech's YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment
CompanyDrug

YolTech’s YOLT-203 Gains Orphan Drug Designation for Primary Hyperoxaluria Type 1 Treatment